

Edmund K Waller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7571931/edmund-k-waller-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230
papers

8,102
citations

42
h-index

85
g-index

242
ext. papers

10,298
ext. citations

5.2
avg. IF

5.79
L-index

#	Paper	IF	Citations
230	PI3K β inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022 , 139, 523-537	2.2	5
229	Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. <i>Cytotherapy</i> , 2022 ,	4.8	1
228	Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
227	HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. <i>Blood</i> , 2021 , 138, 273-282	2.2	15
226	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1865-1877	2.2	18
225	Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2097-2108	9.4	3
224	Indole derivatives, microbiome and graft versus host disease. <i>Current Opinion in Immunology</i> , 2021 , 70, 40-47	7.8	5
223	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 591-599		2
222	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 464-476	8.9	23
221	Development of iron deficiency anemia in patients undergoing extracorporeal photopheresis: Comparison of the UVAR and CELLEX instruments. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 34-40	3.2	1
220	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 4980-4991	7.8	1
219	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K β and δ . <i>Frontiers in Immunology</i> , 2021 , 12, 718621	8.4	3
218	Associations Between Inflammation, Cardiovascular Regenerative Capacity, and Cardiovascular Events: A Cohort Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2814-2822	9.4	0
217	Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. <i>ACS Sensors</i> , 2021 , 6, 3789-3799	9.2	2
216	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	3
215	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1403-1415	21.7	32
214	Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination. <i>Journal of Virology</i> , 2020 , 94,	6.6	9

213	Circulating Progenitor Cells and Cognitive Impairment in Men and Women with Coronary Artery Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 659-668	4.3	2
212	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020 , 105, 1329-1338	6.6	9
211	Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study. <i>Contemporary Clinical Trials</i> , 2020 , 91, 105975	2.3	1
210	Cardiovascular Risk and Resilience Among Black Adults: Rationale and Design of the MECA Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e015247	6	9
209	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 629-637	7.8	28
208	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 39-39	2.2	
207	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020 , 136, 20-21	2.2	
206	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020 , 136, 21-22	2.2	
205	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study 2020 , 8,		13
204	Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease. <i>JAMA Cardiology</i> , 2020 , 5, 147-155	16.2	6
203	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
202	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
201	Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency. <i>JACC Basic To Translational Science</i> , 2020 , 5, 770-782	8.7	2
200	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
199	Stiffness based enrichment of leukemia cells using microfluidics. <i>APL Bioengineering</i> , 2020 , 4, 036101	6.6	3
198	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020 , 123, 1228-1234	8.7	1
197	Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. <i>Science</i> , 2020 , 370, 237-241	33.3	36
196	A new role for an old cytokine: GM-CSF amplifies GVHD. <i>Blood</i> , 2020 , 135, 520-521	2.2	1

195	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020 , 4, 560-572	7.8	40
194	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 740-754	7.8	19
193	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. <i>Molecular Cancer Research</i> , 2019 , 17, 2395-2409	6.6	19
192	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1325-1330	4.7	5
191	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1744-1755	4.7	4
190	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1875-1883	4.7	7
189	KIR Donor Selection: Feasibility in Identifying better Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e28-e32	4.7	21
188	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2002-2007	4.7	32
187	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019 , 3, 2230-2236	7.8	32
186	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019 , 3, 2836-2844	7.8	24
185	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019 , 3, 875-883	7.8	13
184	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2250-2263	7.8	18
183	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
182	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. <i>Blood Advances</i> , 2019 , 3, 2465-2469	7.8	6
181	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019 , 125, 185-193	6.4	3
180	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 699-711	4.7	5
179	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019 , 94, 446-454	7.1	28
178	Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?. <i>Cancer</i> , 2019 , 125, 838-842	6.4	3

177	Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1075-1084	4.7	8
176	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019 , 104, 844-854	6.6	4
175	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019 , 380, 45-56	59.2	1385
174	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 270-278	4.7	14
173	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019 , 54, 490-493	4.4	1
172	Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy. <i>Cell Death and Disease</i> , 2018 , 9, 239	9.8	33
171	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Circulation Research</i> , 2018 , 122, 1565-1575	15.7	22
170	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1069-1071	4.4	1
169	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018 , 124, 2327-2336	10.6	10
168	Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 973-982	4.7	12
167	Microfluidic generation of transient cell volume exchange for convectively driven intracellular delivery of large macromolecules. <i>Materials Today</i> , 2018 , 21, 703-712	21.8	27
166	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018 , 103, 1915-1924	6.6	21
165	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2373-2380	4.7	20
164	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. <i>British Journal of Haematology</i> , 2018 , 182, 887-894	4.5	3
163	Myocardial Ischemia and Mobilization of Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2018 , 7, e007504	6	6
162	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018 , 132, 1015-1015	2.2	2
161	Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients. <i>Blood</i> , 2018 , 132, 899-899	2.2	3
160	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2157-2157	2.2	1

159	Safety and Efficacy of Evomela In Myeloma Autotransplants. <i>Blood</i> , 2018 , 132, 3446-3446	2.2	0
158	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3044-3044	2.2	3
157	Vasoactive Intestinal Peptide Synthesis in Transplant Recipients Critically Regulate Donor T Cell Allereactivity and Graft-Versus-Host Disease. <i>Blood</i> , 2018 , 132, 480-480	2.2	
156	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 521-528	4.7	19
155	Myeloablative busulfan/cytosan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 837-843	1.9	7
154	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	4
153	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. <i>Blood</i> , 2018 , 132, 2506-2519	2.2	78
152	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018 , 9, 2166	8.4	63
151	Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. <i>Nature Communications</i> , 2018 , 9, 3698	17.4	53
150	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018 , 2, 210-223	7.8	50
149	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018 , 2, 299-307	7.8	47
148	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018 , 2, 933-940	7.8	23
147	Circulating Progenitor Cells and Racial Differences. <i>Circulation Research</i> , 2018 , 123, 467-476	15.7	11
146	Flow cytometric data analysis of circulating progenitor cell stability. <i>Data in Brief</i> , 2017 , 10, 346-348	1.2	9
145	GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. <i>Molecular Therapy</i> , 2017 , 25, 416-426	11.7	2
144	Mobilizing plasmacytoid dendritic cells. <i>Blood</i> , 2017 , 129, 2600-2602	2.2	2
143	Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. <i>Oncolmmunology</i> , 2017 , 6, e1304336	7.2	2
142	Microfluidic Sorting of Cells by Viability Based on Differences in Cell Stiffness. <i>Scientific Reports</i> , 2017 , 7, 1997	4.9	43

141	Telomere Shortening, Regenerative Capacity, and Cardiovascular Outcomes. <i>Circulation Research</i> , 2017 , 120, 1130-1138	15.7	46
140	Sex Differences in Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	21
139	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017 , 130, 2243-2250.	2.2	220
138	Building blocks for institutional preparation of CTL019 delivery. <i>Cytotherapy</i> , 2017 , 19, 1015-1024	4.8	46
137	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	30
136	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN γ priming. <i>Blood Advances</i> , 2017 , 1, 628-643	7.8	26
135	PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. <i>PLoS ONE</i> , 2017 , 12, e0184254	3.7	9
134	Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. <i>Oncotarget</i> , 2017 , 8, 81873-81879	3.3	4
133	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1583-1589	13.4	78
132	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. <i>Cancer Research</i> , 2016 , 76, 6802-6815	10.1	7
131	Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease. <i>Circulation Research</i> , 2016 , 119, 564-71	15.7	24
130	Circulating Progenitor Cells is Linked to Cognitive Decline in Healthy Adults. <i>American Journal of the Medical Sciences</i> , 2016 , 351, 147-52	2.2	7
129	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3141-9	2.2	170
128	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. <i>Oncotarget</i> , 2016 , 7, 2936-50	3.3	33
127	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016 , 6,	1	1
126	Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN γ Licensing. <i>Stem Cells</i> , 2016 , 34, 2429-42	5.8	94
125	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016 , 173, 96-104	4.5	43
124	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. <i>Blood</i> , 2016 , 128, 2568-2579	2.2	32

123	Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand) As a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S324-S325	4.7	2
122	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1197-1205	4.7	12
121	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 466-471.e1	2	29
120	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women@ Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD). <i>Atherosclerosis</i> , 2016 , 253, 111-117	3.1	10
119	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1636-1645	4.7	56
118	Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 21-30	4.4	32
117	Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. <i>PLoS Pathogens</i> , 2015 , 11, e1004770	7.6	49
116	Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 206-13		14
115	Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. <i>Circulation Research</i> , 2015 , 116, 289-297	15.7	79
114	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 514-8	2	3
113	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. <i>Science Translational Medicine</i> , 2015 , 7, 315ra191	17.5	41
112	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 383-9	1.9	7
111	Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. <i>Transfusion</i> , 2015 , 55, 259-64	2.9	27
110	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015 , 55, 2351-7	2.9	3
109	Evaluation of the spectra Optia [®] mononuclear cell collection procedure in multiple myeloma patients. <i>Journal of Clinical Apheresis</i> , 2015 , 30, 1-7	3.2	9
108	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR β repertoire. <i>Blood</i> , 2015 , 125, 3835-50	2.2	102
107	A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. <i>Clinical and Translational Immunology</i> , 2015 , 4, e37	6.8	2
106	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 552-8	4.7	9

105	New cancers after autotransplantations for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 738-45	4.7	28
104	Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 934-40	4.7	25
103	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , 2015 , 126, 543-543	2.2	8
102	New molecule for mobilizing marrow stem cells. <i>Blood</i> , 2014 , 123, 310-1	2.2	2
101	Evaluation of peripheral blood stem cell quality in products transported by traditional courier or commercial overnight shipping services. <i>Transfusion</i> , 2014 , 54, 1501-7	2.9	4
100	Circulating progenitor cells are reduced in HIV-positive, anti-retroviral naïve patients. <i>International Journal of Cardiology</i> , 2014 , 176, 1150-2	3.2	0
99	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 89-97	4.7	99
98	Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 852-857	4.7	25
97	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
96	High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 979-85	4.7	33
95	Allotransplantation for patients age \geq 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 960-8	4.7	34
94	Metabolomics of ADSOL (AS-1) red blood cell storage. <i>Transfusion Medicine Reviews</i> , 2014 , 28, 41-55	7.4	68
93	Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 360-9	4	6
92	Chemokine and lymph node homing receptor expression on pDC vary by graft source. <i>Oncolmmunology</i> , 2014 , 3, e958957	7.2	5
91	Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. <i>Cancer Medicine</i> , 2014 , 3, 215-24	4.8	40
90	Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2365-72	2.2	62
89	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 16	22.4	6
88	Circadian variation in vascular function and regenerative capacity in healthy humans. <i>Journal of the American Heart Association</i> , 2014 , 3, e000845	6	32

87	Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. <i>PLoS ONE</i> , 2014 , 9, e96165	3.7	21
86	Incidence and geographic distribution of adult acute leukemia in the state of Georgia. <i>Southern Medical Journal</i> , 2014 , 107, 497-500	0.6	1
85	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , 2013 , 53, 76-84	2.9	3
84	In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1638-49	4.7	84
83	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4199-206	2.2	384
82	Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2631-9	27.4	24
81	Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1331-9	4.7	8
80	Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1393-5	4.7	14
79	VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. <i>PLoS ONE</i> , 2013 , 8, e63381	3.7	8
78	From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. <i>BioMed Research International</i> , 2013 , 2013, 929842	3	7
77	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013 , 121, 197-206	2.2	106
76	Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. <i>Blood</i> , 2013 , 121, 2347-51	2.2	7
75	Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice. <i>PLoS ONE</i> , 2013 , 8, e64837	3.7	7
74	Allogeneic HSCT Patients Receiving More RBC Transfusions Are At Increased Risk For Development Of Grade 2-4 Acute Graft-Versus-Host Disease. <i>Blood</i> , 2013 , 122, 3298-3298	2.2	1
73	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013 , 122, 768-768	2.2	
72	Expression Of PD-L1 Is Required To Control Acute GvHD In Allo-HSCT Recipients. <i>Blood</i> , 2013 , 122, 2008-2008		
71	VIP-Receptor Antagonist Enhanced Antileukemic Activity In Mice. <i>Blood</i> , 2013 , 122, 1664-1664	2.2	
70	IFN- γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. <i>Blood</i> , 2012 , 119, 1075-85	2.2	67

69	Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. <i>Journal of Immunology</i> , 2012 , 189, 5082-8	5.3	253
68	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1287-94	4.7	29
67	Natural suppressor cells; past, present and future. <i>Frontiers in Bioscience - Elite</i> , 2012 , 4, 1237-45	1.6	5
66	Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> , 2012 , 367, 1487-96	59.2	620
65	Natural suppressor cells past present and future. <i>Frontiers in Bioscience - Elite</i> , 2012 , E4, 1237-1245	1.6	5
64	Advanced Non Small Cell Lung Cancer Patients with Fewer Numbers of Blood Myeloid Dendritic Cells and CD4 Cells Prior to Treatment Have Inferior Progression-Free Survival: Implications for Cancer Immunotherapy. <i>Blood</i> , 2012 , 120, 4837-4837	2.2	
63	Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia. <i>Blood</i> , 2012 , 120, 4309-4309	2.2	
62	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. <i>Blood</i> , 2012 , 120, 741-741	2.2	1
61	Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. <i>Journal of Immunology</i> , 2011 , 187, 5130-40	5.3	39
60	Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011 , 117, 6963-70	2.2	283
59	A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2011 , 51, 1779-83	2.9	1
58	Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. <i>Transfusion</i> , 2011 , 51, 2175-82	2.9	84
57	Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011 , 5, 372	1.2	3
56	Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. <i>Journal of Immunology</i> , 2011 , 187, 1057-65	5.3	25
55	Flagellin, a TLR5 Agonist, Reduces GvHD in Allogeneic HSCT Recipients While Enhancing Anti-Viral Immunity: A Novel Therapeutic Approach. <i>Blood</i> , 2011 , 118, 144-144	2.2	
54	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. <i>Blood</i> , 2011 , 118, 1959-1959	2.2	
53	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , 2011 , 118, 2988-2988	2.2	
52	Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥5 Years. <i>Blood</i> , 2011 , 118, 1015-1015	2.2	

51	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. <i>Transfusion</i> , 2010 , 50, 2424-31	2.9	19
50	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. <i>Blood</i> , 2010 , 116, 2305-2305	2.2	1
49	Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment. <i>Blood</i> , 2010 , 116, 4909-4909	2.2	
48	Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. <i>Journal of Immunology</i> , 2009 , 183, 7799-809	5.3	21
47	Autoimmune neutropenia in adults. <i>Autoimmunity Reviews</i> , 2009 , 9, 62-6	13.6	64
46	Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1347-53	4.7	53
45	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <i>Immunotherapy</i> , 2009 , 1, 599-621	3.8	51
44	Donor Dendritic Cells Home to Lymphoid Organs in Allogeneic Transplant Recipients, Enhance Donor T-Cell Chimerism, and Polarize Donor T-Cell Activation.. <i>Blood</i> , 2009 , 114, 62-62	2.2	
43	Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.. <i>Blood</i> , 2009 , 114, 1165-1165	2.2	
42	A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 4230-4230	2.2	
41	Prophylactic Use of Flagellin: A Novel Method to Boost Immune Reconstitution in Allogeneic HSCT Recipients with Limited GvHD.. <i>Blood</i> , 2009 , 114, 3561-3561	2.2	
40	Targeting PKCtheta Inhibits Alloreactivity and Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia and Anti-Infection Activities.. <i>Blood</i> , 2009 , 114, 2458-2458	2.2	
39	Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. <i>Journal of Immunology</i> , 2008 , 180, 6892-902	5.3	11
38	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2008 , 112, 3332-3332	2.2	1
37	Allogeneic Transplantation for Multiple Myeloma 2008 , 125-142		
36	Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies. <i>Blood</i> , 2008 , 112, 2664-2664	2.2	
35	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. <i>Blood</i> , 2008 , 112, 3644-3644	2.2	
34	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2008 , 112, 1183-1183	2.2	

33	Flagellin, a TLR5 Agonist, Down-Regulate CD62L on Donor T Cells and Limit GvHD in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 3521-3521	2.2	
32	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007 , 47, 629-35	2.9	16
31	Chronic GvHD decreases antiviral immune responses in allogeneic BMT. <i>Blood</i> , 2007 , 109, 4548-56	2.2	25
30	The role of sargramostim (rhGM-CSF) as immunotherapy. <i>Oncologist</i> , 2007 , 12 Suppl 2, 22-6	5.7	311
29	Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 116-23	4.7	79
28	Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 746-7	4.7	8
27	Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 895-904	4.7	14
26	The Absence of Vasoactive Intestinal Peptide Augments Allo-Reactivity and the Anti-Viral Response in Bone Marrow Transplantation.. <i>Blood</i> , 2007 , 110, 3267-3267	2.2	1
25	Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT. <i>Experimental Hematology</i> , 2006 , 34, 895-904	3.1	6
24	Vaccinia Virus Tropism for Primary Hematolymphoid Cells Is Determined by Restricted Expression of a Unique Virus Receptor. <i>Journal of Virology</i> , 2006 , 80, 3126-3126	6.6	78
23	Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 169-80	4.7	8
22	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. <i>Blood</i> , 2005 , 106, 4634-4634	2.2	
21	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. <i>Blood</i> , 2005 , 106, 2016-2016	2.2	
20	Prophylactic Amotosalen-Treated Donor T-Cells Prevent Late CMV Infection in Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2005 , 106, 3024-3024	2.2	
19	Cellular immunotherapy and cancer. <i>Seminars in Oncology</i> , 2004 , 31, 87-90	5.5	11
18	Reconstructing immunity after allogeneic transplantation. <i>Immunologic Research</i> , 2004 , 29, 269-82	4.3	19
17	Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 540-51	4.7	29
16	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 818-57	4.7	38

15	Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. <i>Blood Cells, Molecules, and Diseases</i> , 2004 , 33, 233-7	2.1	25
14	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg [®]) for Advanced MDS and Secondary or Relapsed AML.. <i>Blood</i> , 2004 , 104, 1814-1814	2.2	2
13	MCMV Infection Lowers the Threshold for the Development of Clinical GvHD after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004 , 104, 2125-2125	2.2	
12	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. <i>Blood</i> , 2004 , 104, 3159-3159	2.2	
11	Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. <i>Journal of Immunology</i> , 2003 , 171, 6023-31	5.3	23
10	Modulation of antitumor immune responses by hematopoietic cytokines. <i>Cancer</i> , 2003 , 97, 1797-809	6.4	19
9	Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 460-71	4.7	104
8	Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 616-32	4.7	28
7	Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. <i>Blood</i> , 2002 , 99, 1085-8	2.2	67
6	Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , 2001 , 97, 2948-56	2.2	119
5	CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001 , 49, 629-40	7.4	42
4	Changes in the pattern of TCR V beta repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. <i>British Journal of Haematology</i> , 2001 , 113, 224-30	4.5	5
3	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999 , 94, 3222-3233	2.2	51
2	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999 , 94, 3222-3233	2.2	6
1	Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic Progenitors. <i>Blood</i> , 1998 , 91, 2588-2600	2.2	154